Dr. NI Xiayun

倪夏昀

Post-doctoral Fellow

PhD

Field of Research

Clinical and basic research of metabolic cardiovascular diseases

Biography

Dr. Xiayun NI is currently a Post-doctoral Fellow in the Department of Medicine, School of Clinical Medicine, The University of Hong Kong, where she is undergoing postdoctoral training. She earned her Ph.D. from University of Science and Technology of China in 2025. Her current research focuses on clinical and basic research of metabolic cardiovascular diseases.

Publications

Ni XY#, Feng XJ#, Wang ZH#, Little PJ, Cao Y, Xu SW*, Tang LQ*, Weng JP*. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacologica Sinica, 2024. 45, 1604–1617.
Ni XY#, Zhang L#, Feng XJ*, Tang LQ*. New hypoglycemic drugs: combination drugs and targets discovery. Frontiers in Pharmacology, 2022. 13, 877797.
Deng MY#, Ni XY#, Chen S#, Feng XJ*, Wang ZH*. Single-cell atlas reveals that Empagliflozin promotes myocyte communication via CDH2 and VEGF to improve HFpEF. Cardiology Plus, 2025.
Feng XJ#, Ni XY#, Wang ZH, Xu SW*, Tang LQ*, Weng JP*. ACLY mitigates pathological cardiac remodeling by suppressing mitochondrial protein acetylation and ROS. (Under review)

Other Information:

1. Special Prize for Outstanding Students (TOP 1%), 2019